Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 781 to 792 of 808 entries
Sorted by: Best Match Show Resources per page
Ketamine: A Potential Adjunct for Severe Benzodiazepine Withdrawal.

Cureus

Purcell K, Bianchi PW, Glenn D, Blakey B, Motov S.
PMID: 35003959
Cureus. 2021 Dec 02;13(12):e20114. doi: 10.7759/cureus.20114. eCollection 2021 Dec.

Following the abrupt cessation of benzodiazepine therapy, patients can present with acute life-threatening withdrawal. Medical management of benzodiazepine withdrawal is typically undertaken with benzodiazepines either through loading dose with gradual taper or symptom triggered treatment, though adjuvant anxiolytics and...

Cite
Purcell K, Bianchi PW, Glenn D, et al. Ketamine: A Potential Adjunct for Severe Benzodiazepine Withdrawal. Cureus. 2021;13(12):e20114doi: 10.7759/cureus.20114.
Purcell, K., Bianchi, P. W., Glenn, D., Blakey, B., & Motov, S. (2021). Ketamine: A Potential Adjunct for Severe Benzodiazepine Withdrawal. Cureus, 13(12), e20114. https://doi.org/10.7759/cureus.20114
Purcell, Kristen, et al. "Ketamine: A Potential Adjunct for Severe Benzodiazepine Withdrawal." Cureus vol. 13,12 (2021): e20114. doi: https://doi.org/10.7759/cureus.20114
Purcell K, Bianchi PW, Glenn D, Blakey B, Motov S. Ketamine: A Potential Adjunct for Severe Benzodiazepine Withdrawal. Cureus. 2021 Dec 02;13(12):e20114. doi: 10.7759/cureus.20114. eCollection 2021 Dec. PMID: 35003959; PMCID: PMC8723697.
Copy Download .nbib Format: NLM
Plasma unmetabolized folic acid in pregnancy and risk of autistic traits and language impairment in antiseizure medication-exposed children of women with epilepsy.

The American journal of clinical nutrition

Husebye ESN, Wendel AWK, Gilhus NE, Riedel B, Bjørk MH.
PMID: 34994378
Am J Clin Nutr. 2022 Jan 05; doi: 10.1093/ajcn/nqab436. Epub 2022 Jan 05.

BACKGROUND: Fetal exposure to unmetabolized folic acid (UMFA) during pregnancy may be associated with adverse neurodevelopment. Antiseizure medication (ASM) may interact with folate metabolism. Women with epilepsy using ASM are often recommended high-dose folic acid supplement use during pregnancy.OBJECTIVES:...

Cite
Husebye ESN, Wendel AWK, Gilhus NE, et al. Plasma unmetabolized folic acid in pregnancy and risk of autistic traits and language impairment in antiseizure medication-exposed children of women with epilepsy. Am J Clin Nutr. 2022;doi: 10.1093/ajcn/nqab436.
Husebye, E. S. N., Wendel, A. W. K., Gilhus, N. E., Riedel, B., & Bjørk, M. H. (2022). Plasma unmetabolized folic acid in pregnancy and risk of autistic traits and language impairment in antiseizure medication-exposed children of women with epilepsy. The American journal of clinical nutrition, . https://doi.org/10.1093/ajcn/nqab436
Husebye, Elisabeth Synnøve Nilsen, et al. "Plasma unmetabolized folic acid in pregnancy and risk of autistic traits and language impairment in antiseizure medication-exposed children of women with epilepsy." The American journal of clinical nutrition vol. (2022). doi: https://doi.org/10.1093/ajcn/nqab436
Husebye ESN, Wendel AWK, Gilhus NE, Riedel B, Bjørk MH. Plasma unmetabolized folic acid in pregnancy and risk of autistic traits and language impairment in antiseizure medication-exposed children of women with epilepsy. Am J Clin Nutr. 2022 Jan 05; doi: 10.1093/ajcn/nqab436. Epub 2022 Jan 05. PMID: 34994378.
Copy Download .nbib Format: NLM
Lacosamide Inhibition of Na.

Frontiers in pharmacology

Labau JIR, Alsaloum M, Estacion M, Tanaka B, Dib-Hajj FB, Lauria G, Smeets HJM, Faber CG, Dib-Hajj S, Waxman SG.
PMID: 34992539
Front Pharmacol. 2021 Dec 21;12:791740. doi: 10.3389/fphar.2021.791740. eCollection 2021.

Lacosamide, developed as an anti-epileptic drug, has been used for the treatment of pain. Unlike typical anticonvulsants and local anesthetics which enhance fast-inactivation and bind within the pore of sodium channels, lacosamide enhances slow-inactivation of these channels, suggesting different...

Cite
Labau JIR, Alsaloum M, Estacion M, et al. Lacosamide Inhibition of Na. Front Pharmacol. 2021;12:791740doi: 10.3389/fphar.2021.791740.
Labau, J. I. R., Alsaloum, M., Estacion, M., Tanaka, B., Dib-Hajj, F. B., Lauria, G., Smeets, H. J. M., Faber, C. G., Dib-Hajj, S., & Waxman, S. G. (2021). Lacosamide Inhibition of Na. Frontiers in pharmacology, 12791740. https://doi.org/10.3389/fphar.2021.791740
Labau, Julie I R, et al. "Lacosamide Inhibition of Na." Frontiers in pharmacology vol. 12 (2021): 791740. doi: https://doi.org/10.3389/fphar.2021.791740
Labau JIR, Alsaloum M, Estacion M, Tanaka B, Dib-Hajj FB, Lauria G, Smeets HJM, Faber CG, Dib-Hajj S, Waxman SG. Lacosamide Inhibition of Na. Front Pharmacol. 2021 Dec 21;12:791740. doi: 10.3389/fphar.2021.791740. eCollection 2021. PMID: 34992539; PMCID: PMC8724789.
Copy Download .nbib Format: NLM
Early Diagnosis of Stevens-Johnson Syndrome in the Dental Clinic Setting.

Cureus

Al Hathlol WK, Almeslet A.
PMID: 33936873
Cureus. 2021 Mar 28;13(3):e14160. doi: 10.7759/cureus.14160.

Stevens-Johnson syndrome (SJS) is a life-threatening acute and fatal dermatological disease. It can present with many variations and rapidly worsens in a short period of time. Early diagnosis and management play an important role in stopping SJS from progression....

Cite
Al Hathlol WK, Almeslet A. Early Diagnosis of Stevens-Johnson Syndrome in the Dental Clinic Setting. Cureus. 2021;13(3):e14160doi: 10.7759/cureus.14160.
Al Hathlol, W. K., & Almeslet, A. (2021). Early Diagnosis of Stevens-Johnson Syndrome in the Dental Clinic Setting. Cureus, 13(3), e14160. https://doi.org/10.7759/cureus.14160
Al Hathlol, Wisam K, and Almeslet, Asma. "Early Diagnosis of Stevens-Johnson Syndrome in the Dental Clinic Setting." Cureus vol. 13,3 (2021): e14160. doi: https://doi.org/10.7759/cureus.14160
Al Hathlol WK, Almeslet A. Early Diagnosis of Stevens-Johnson Syndrome in the Dental Clinic Setting. Cureus. 2021 Mar 28;13(3):e14160. doi: 10.7759/cureus.14160. PMID: 33936873; PMCID: PMC8078824.
Copy Download .nbib Format: NLM
SOP: First-ever epileptic seizure in adult patients.

Neurological research and practice

Bösel J.
PMID: 33324869
Neurol Res Pract. 2019 Feb 28;1:3. doi: 10.1186/s42466-019-0006-4. eCollection 2019.

BACKGROUND: About 5% of all adults will have at least one epileptic seizure in their life. The incidence of all unprovoked seizures ranges from approximately 50 to 70 /100,000. The very first epileptic seizure in an adult can be...

Cite
Bösel J. SOP: First-ever epileptic seizure in adult patients. Neurol Res Pract. 2019;1:3doi: 10.1186/s42466-019-0006-4.
Bösel, J. (2019). SOP: First-ever epileptic seizure in adult patients. Neurological research and practice, 13. https://doi.org/10.1186/s42466-019-0006-4
Bösel, Julian. "SOP: First-ever epileptic seizure in adult patients." Neurological research and practice vol. 1 (2019): 3. doi: https://doi.org/10.1186/s42466-019-0006-4
Bösel J. SOP: First-ever epileptic seizure in adult patients. Neurol Res Pract. 2019 Feb 28;1:3. doi: 10.1186/s42466-019-0006-4. eCollection 2019. PMID: 33324869; PMCID: PMC7650127.
Copy Download .nbib Format: NLM
Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome.

Burns : journal of the International Society for Burn Injuries

de Bustros P, Baldea A, Sanford A, Joyce C, Adams W, Bouchard C.
PMID: 34924230
Burns. 2021 Aug 18; doi: 10.1016/j.burns.2021.08.009. Epub 2021 Aug 18.

PURPOSE: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are severe and potentially lethal adverse drug reactions characterized by acute inflammation of the skin, mucous membranes, and ocular surface that typically occurs within weeks of a culprit drug...

Cite
de Bustros P, Baldea A, Sanford A, et al. Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome. Burns. 2021;doi: 10.1016/j.burns.2021.08.009.
de Bustros, P., Baldea, A., Sanford, A., Joyce, C., Adams, W., & Bouchard, C. (2021). Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome. Burns : journal of the International Society for Burn Injuries, . https://doi.org/10.1016/j.burns.2021.08.009
de Bustros, Paul, et al. "Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome." Burns : journal of the International Society for Burn Injuries vol. (2021). doi: https://doi.org/10.1016/j.burns.2021.08.009
de Bustros P, Baldea A, Sanford A, Joyce C, Adams W, Bouchard C. Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome. Burns. 2021 Aug 18; doi: 10.1016/j.burns.2021.08.009. Epub 2021 Aug 18. PMID: 34924230.
Copy Download .nbib Format: NLM
Continuous Electroencephalogram and Antiseizure Medication Use in an International Pediatric Traumatic Brain Injury Population.

Neurocritical care

Snooks KC, Yan K, Farias-Moeller R, Fink EL, Hanson SJ.
PMID: 34553297
Neurocrit Care. 2021 Sep 22; doi: 10.1007/s12028-021-01337-7. Epub 2021 Sep 22.

BACKGROUND: Electrographic seizures are frequent and associated with worse outcomes following traumatic brain injury (TBI). Despite this, the use of continuous electroencephalogram (cEEG) remains low. Our study describes cEEG usage and treatment dosing antiseizure medications (ASMs) in an international...

Cite
Snooks KC, Yan K, Farias-Moeller R, et al. Continuous Electroencephalogram and Antiseizure Medication Use in an International Pediatric Traumatic Brain Injury Population. Neurocrit Care. 2021;doi: 10.1007/s12028-021-01337-7.
Snooks, K. C., Yan, K., Farias-Moeller, R., Fink, E. L., & Hanson, S. J. (2021). Continuous Electroencephalogram and Antiseizure Medication Use in an International Pediatric Traumatic Brain Injury Population. Neurocritical care, . https://doi.org/10.1007/s12028-021-01337-7
Snooks, Kellie C, et al. "Continuous Electroencephalogram and Antiseizure Medication Use in an International Pediatric Traumatic Brain Injury Population." Neurocritical care vol. (2021). doi: https://doi.org/10.1007/s12028-021-01337-7
Snooks KC, Yan K, Farias-Moeller R, Fink EL, Hanson SJ. Continuous Electroencephalogram and Antiseizure Medication Use in an International Pediatric Traumatic Brain Injury Population. Neurocrit Care. 2021 Sep 22; doi: 10.1007/s12028-021-01337-7. Epub 2021 Sep 22. PMID: 34553297.
Copy Download .nbib Format: NLM
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.

Advances in therapy

Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW.
PMID: 34874514
Adv Ther. 2021 Dec 07; doi: 10.1007/s12325-021-01923-3. Epub 2021 Dec 07.

INTRODUCTION: Ubrogepant is a calcitonin gene-related peptide receptor antagonist indicated for acute treatment of migraine that can be used to treat breakthrough attacks in individuals taking preventive treatment for migraine. We evaluated the impact of preventive medication use on...

Cite
Blumenfeld AM, Knievel K, Manack Adams A, et al. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Adv Ther. 2021;doi: 10.1007/s12325-021-01923-3.
Blumenfeld, A. M., Knievel, K., Manack Adams, A., Severt, L., Butler, M., Lai, H., & Dodick, D. W. (2021). Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Advances in therapy, . https://doi.org/10.1007/s12325-021-01923-3
Blumenfeld, Andrew M, et al. "Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials." Advances in therapy vol. (2021). doi: https://doi.org/10.1007/s12325-021-01923-3
Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Adv Ther. 2021 Dec 07; doi: 10.1007/s12325-021-01923-3. Epub 2021 Dec 07. PMID: 34874514.
Copy Download .nbib Format: NLM
Pharmacogenetic testing in psychiatry and neurology: an overview of reviews.

Pharmacogenomics

Lara DV, Melo DO, Silva RAM, Santos PCJL.
PMID: 33973477
Pharmacogenomics. 2021 Jun;22(8):505-513. doi: 10.2217/pgs-2020-0187. Epub 2021 May 11.

Pharmacogenetic testing is available to healthcare professionals to guide drug selection and prevent adverse events. However, its implementation in the clinical practice of psychiatry/neurology still has barriers, mainly due to a lack of evidence. We conducted a literature search...

Cite
Lara DV, Melo DO, Silva RAM, et al. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics. 2021;22(8):505-513doi: 10.2217/pgs-2020-0187.
Lara, D. V., Melo, D. O., Silva, R. A. M., & Santos, P. C. J. L. (2021). Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics, 22(8), 505-513. https://doi.org/10.2217/pgs-2020-0187
Lara, Danilo Vieira de, et al. "Pharmacogenetic testing in psychiatry and neurology: an overview of reviews." Pharmacogenomics vol. 22,8 (2021): 505-513. doi: https://doi.org/10.2217/pgs-2020-0187
Lara DV, Melo DO, Silva RAM, Santos PCJL. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics. 2021 Jun;22(8):505-513. doi: 10.2217/pgs-2020-0187. Epub 2021 May 11. PMID: 33973477.
Copy Download .nbib Format: NLM
Barbiturates: A Review of Synthesis and Antimicrobial Research Progress.

Current organic synthesis

Madhvi, Utreja D, Sharma S.
PMID: 33855946
Curr Org Synth. 2021 Apr 13; doi: 10.2174/1570179418666210414104857. Epub 2021 Apr 13.

BACKGROUND: Barbituric acid and its derivatives have turned heads for several years as an indispensable class of compounds in the pharmaceutical industry because of their vast assortment of biological activities such as anticonvulsants, hypnotics, anti-diabetic, antiviral, anti-AIDS, anti-cancer, anti-microbial...

Cite
Madhvi, Utreja D, Sharma S. Barbiturates: A Review of Synthesis and Antimicrobial Research Progress. Curr Org Synth. 2021;doi: 10.2174/1570179418666210414104857.
Madhvi, Utreja, D., & Sharma, S. (2021). Barbiturates: A Review of Synthesis and Antimicrobial Research Progress. Current organic synthesis, . https://doi.org/10.2174/1570179418666210414104857
Madhvi, et al. "Barbiturates: A Review of Synthesis and Antimicrobial Research Progress." Current organic synthesis vol. (2021). doi: https://doi.org/10.2174/1570179418666210414104857
Madhvi, Utreja D, Sharma S. Barbiturates: A Review of Synthesis and Antimicrobial Research Progress. Curr Org Synth. 2021 Apr 13; doi: 10.2174/1570179418666210414104857. Epub 2021 Apr 13. PMID: 33855946.
Copy Download .nbib Format: NLM
Chronic Pain Treatment Strategies in Parkinson's Disease.

Neurology international

Edinoff A, Sathivadivel N, McBride T, Parker A, Okeagu C, Kaye AD, Kaye AM, Kaye JS, Kaye RJ, M Sheth M, Viswanath O, Urits I.
PMID: 33218135
Neurol Int. 2020 Nov 18;12(3):61-76. doi: 10.3390/neurolint12030014.

Neurological disorders, including Parkinson's disease (PD), have increased in prevalence and are expected to further increase in the coming decades. In this regard, PD affects around 3% of the population by age 65 and up to 5% of people...

Cite
Edinoff A, Sathivadivel N, McBride T, et al. Chronic Pain Treatment Strategies in Parkinson's Disease. Neurol Int. 2020;12(3):61-76doi: 10.3390/neurolint12030014.
Edinoff, A., Sathivadivel, N., McBride, T., Parker, A., Okeagu, C., Kaye, A. D., Kaye, A. M., Kaye, J. S., Kaye, R. J., M Sheth, M., Viswanath, O., & Urits, I. (2020). Chronic Pain Treatment Strategies in Parkinson's Disease. Neurology international, 12(3), 61-76. https://doi.org/10.3390/neurolint12030014
Edinoff, Amber, et al. "Chronic Pain Treatment Strategies in Parkinson's Disease." Neurology international vol. 12,3 (2020): 61-76. doi: https://doi.org/10.3390/neurolint12030014
Edinoff A, Sathivadivel N, McBride T, Parker A, Okeagu C, Kaye AD, Kaye AM, Kaye JS, Kaye RJ, M Sheth M, Viswanath O, Urits I. Chronic Pain Treatment Strategies in Parkinson's Disease. Neurol Int. 2020 Nov 18;12(3):61-76. doi: 10.3390/neurolint12030014. PMID: 33218135; PMCID: PMC7768530.
Copy Download .nbib Format: NLM
Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis.

The Korean journal of pain

Kim J, Kim MK, Choi GJ, Shin HY, Kim BG, Kang H.
PMID: 34593669
Korean J Pain. 2021 Oct 01;34(4):509-533. doi: 10.3344/kjp.2021.34.4.509.

BACKGROUND: Postherpetic neuralgia (PHN) is a refractory complication of herpes zoster (HZ). To prevent PHN, various strategies have been aggressively adopted. However, the efficacy of these strategies remains controversial. Therefore, we aimed to estimate the relative efficacy of various...

Cite
Kim J, Kim MK, Choi GJ, et al. Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. Korean J Pain. 2021;34(4):509-533doi: 10.3344/kjp.2021.34.4.509.
Kim, J., Kim, M. K., Choi, G. J., Shin, H. Y., Kim, B. G., & Kang, H. (2021). Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. The Korean journal of pain, 34(4), 509-533. https://doi.org/10.3344/kjp.2021.34.4.509
Kim, Junhyeok, et al. "Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis." The Korean journal of pain vol. 34,4 (2021): 509-533. doi: https://doi.org/10.3344/kjp.2021.34.4.509
Kim J, Kim MK, Choi GJ, Shin HY, Kim BG, Kang H. Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. Korean J Pain. 2021 Oct 01;34(4):509-533. doi: 10.3344/kjp.2021.34.4.509. PMID: 34593669; PMCID: PMC8494957.
Copy Download .nbib Format: NLM
Showing 781 to 792 of 808 entries